Disease ⇒ Thrombotic events {40000154}

Record Keys

Parent:[  ]
Thrombotic events


Initialisation date:
Other Terms:[  ]

Meta Information

MedDra ID:[  ]
MedDra Level:[  ]
ICD:[  ]
Category:[  ]
Zone:[  ]
Mechanism:[  ]


[  ]

Shared Reference Notes

  • [1.1
    - #TMAO was found to contribute to thrombotic events by causing platelet hyperactivity
  • [1.2
    - #TMAO has a direct effect on platelets, increasing platelet reactivity and thrombosis through altered intracellular calcium signals elicited by a variety of agonists.
  • [1.3] [#Acylcarnitines] [#Antibiotic Therapy
    - #2-methylbutyrylcarnitine (2MBC), a branched-chain acylcarnitine, is accumulated in patients with #Covid-19 and in patients with major adverse cardiovascular events (MACEs). - 2MBC enhances platelet hyperreactivity and thrombus formation in mice. - 2MBC binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. - Genetic depletion or pharmacological inhibition of integrin α2β1 largely reverses the pro-thrombotic effects of 2MBC. - 2MBC can be generated in a gut-microbiota-dependent manner, whereas the accumulation of plasma 2MBC and its thrombosis-aggravating effect are largely ameliorated following antibiotic-induced microbial depletion.

References Notes

[  ]

Common References

MetaBiom only uses strictly necessary session cookies to give you the best possible experience on the website. By selecting "Accept essential cookies" you agree to the use of these cookies.